• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer.

作者信息

Jensen Kristian Hastoft, Persson Gitte, Bondgaard Anna-Louise, Pøhl Mette

机构信息

a Department of Oncology , Rigshospitalet Copenhagen University Hospital , Copenhagen , Denmark.

b Department of Pathology , Rigshospitalet Copenhagen University Hospital , Copenhagen , Denmark.

出版信息

Acta Oncol. 2018 Aug;57(8):1127-1128. doi: 10.1080/0284186X.2018.1433877. Epub 2018 Jan 31.

DOI:10.1080/0284186X.2018.1433877
PMID:29384034
Abstract
摘要

相似文献

1
Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer.非小细胞肺癌抗PD-1治疗后发生的肺结核
Acta Oncol. 2018 Aug;57(8):1127-1128. doi: 10.1080/0284186X.2018.1433877. Epub 2018 Jan 31.
2
Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.纳武利尤单抗治疗晚期转移性非小细胞肺癌的日本患者：疗效和安全性临床试验证据的综述。
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618801167. doi: 10.1177/1753466618801167.
3
Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient.抗PD-1免疫检查点抑制剂在肝移植受者中的安全性。
Ann Oncol. 2018 Jan 1;29(1):286-287. doi: 10.1093/annonc/mdx548.
4
Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient.纳武单抗诱导的转移性非小细胞肺癌患者免疫性血小板减少症
Oncol Res Treat. 2017;40(10):621-622. doi: 10.1159/000477968. Epub 2017 Sep 19.
5
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient.非小细胞肺癌患者接受纳武单抗治疗期间出现的与抗程序性死亡蛋白1相关的冷球蛋白血症。
Ann Oncol. 2017 Jun 1;28(6):1405-1406. doi: 10.1093/annonc/mdx126.
6
Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents.一名接受纳武单抗治疗后再使用抗结核分枝杆菌药物的非小细胞肺癌患者出现的矛盾反应。
J Infect Chemother. 2019 Jan;25(1):54-58. doi: 10.1016/j.jiac.2018.06.016. Epub 2018 Jul 25.
7
Severe pulmonary infections complicating nivolumab treatment for lung cancer: a report of two cases.严重肺部感染合并纳武利尤单抗治疗肺癌：两例报告。
Acta Clin Belg. 2020 Aug;75(4):308-310. doi: 10.1080/17843286.2019.1629078. Epub 2019 Jun 9.
8
New onset of psoriasis during nivolumab treatment for lung cancer.在使用纳武单抗治疗肺癌期间新发银屑病。
J Dermatol. 2018 Mar;45(3):e55-e56. doi: 10.1111/1346-8138.14167. Epub 2017 Dec 4.
9
Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis.广泛期小细胞肺癌对单药纳武单抗持续完全缓解并伴有免疫相关皮炎
Clin Lung Cancer. 2020 Jan;21(1):e6-e9. doi: 10.1016/j.cllc.2019.09.005. Epub 2019 Sep 26.
10
Late Gastrointestinal Toxicity During Nivolumab Therapy in Non-Small Cell Lung Cancer: A Rare Case of Inflammatory Bowel Disease.纳武单抗治疗非小细胞肺癌期间的晚期胃肠道毒性：一例罕见的炎症性肠病病例
J Thorac Oncol. 2018 Aug;13(8):e152-e153. doi: 10.1016/j.jtho.2018.03.022.

引用本文的文献

1
Simultaneous Anti-Tuberculosis and Anti-Tumor Treatment with Immune Checkpoint Inhibitors for Co-Existent Pulmonary Tuberculosis and Advanced Lung Cancer.免疫检查点抑制剂同步抗结核与抗肿瘤治疗并存的肺结核和晚期肺癌
Infect Drug Resist. 2025 Jan 6;18:107-112. doi: 10.2147/IDR.S497006. eCollection 2025.
2
A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does Goldilocks have the answer?关于使用免疫检查点抑制剂引发分枝杆菌感染风险争议的叙述性综述：金发姑娘知道答案吗？
J Thorac Dis. 2024 Feb 29;16(2):1601-1624. doi: 10.21037/jtd-23-1395. Epub 2024 Feb 27.
3
Pulmonary Tuberculosis Following Immune Checkpoint Inhibitor Treatment for Recurrent Maxillary Squamous Cell Carcinoma.
免疫检查点抑制剂治疗复发性上颌鳞状细胞癌后发生的肺结核
Cureus. 2024 Jan 29;16(1):e53203. doi: 10.7759/cureus.53203. eCollection 2024 Jan.
4
Increased Tuberculosis Incidence Due to Immunotherapy Based on PD-1 and PD-L1 Blockade: A Systematic Review and Meta-Analysis.免疫治疗药物阻断 PD-1/PD-L1 通路导致的结核病发病率增加：一项系统评价和荟萃分析。
Front Immunol. 2022 May 19;13:727220. doi: 10.3389/fimmu.2022.727220. eCollection 2022.
5
The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with infection.抗程序性细胞死亡蛋白1单克隆抗体免疫疗法治疗合并感染的肺癌的安全性和有效性
Transl Lung Cancer Res. 2021 Oct;10(10):3929-3942. doi: 10.21037/tlcr-21-524.
6
Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report.免疫检查点抑制剂 pembrolizumab 治疗转移性鼻咽癌后引起回肠结核再激活：一例报告。
BMC Infect Dis. 2021 Nov 10;21(1):1148. doi: 10.1186/s12879-021-06845-7.
7
Exacerbation of nontuberculous mycobacterial pulmonary disease in a patient with advanced non-small-cell lung cancer during treatment with PD-1 inhibitor and chemotherapy.一名晚期非小细胞肺癌患者在接受PD-1抑制剂和化疗治疗期间非结核分枝杆菌肺病病情加重。
Respir Med Case Rep. 2021 Oct 21;34:101529. doi: 10.1016/j.rmcr.2021.101529. eCollection 2021.
8
Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy.免疫失调相关感染：癌症免疫治疗的一种新出现的并发症。
Thorax. 2022 Mar;77(3):304-311. doi: 10.1136/thoraxjnl-2021-217260. Epub 2021 Oct 4.
9
Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study.免疫检查点抑制剂治疗的癌症患者的结核病风险：一项全国性观察研究。
J Immunother Cancer. 2021 Sep;9(9). doi: 10.1136/jitc-2021-002960.
10
Immune Checkpoint Inhibitors in Special Populations.免疫检查点抑制剂在特殊人群中的应用。
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211036526. doi: 10.1177/15330338211036526.